Antibody–drug conjugates: What drives their progress?
Giulia Pander, Philipp Uhl, Nikos Kühl, Uwe Haberkorn, Jan Anderl, Walter Mier
Topics & Concepts
Bystander effectDrugImmune systemAntibody-drug conjugatePharmacologyMedicineTumor microenvironmentAntibodyToxicityCancer researchImmunologyMonoclonal antibodyInternal medicineHER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchCAR-T cell therapy research